#4 - Johnson & Johnson (NYSE:JNJ)
The final defensive stock on this list is Johnson & Johnson (NYSE:JNJ). As with many sectors, there are several attractive options in the pharmaceutical space. Some people may prefer Pfizer (NYSE:PFE), I’ll give the nod to JNJ because it offers exposure to both the pharmaceutical and consumer essentials space.
But that’s also why JNJ may not be a long-term play. The stock is showing tepid growth this year after the company announced it was going to spin off its consumer products division into a separate company. This is projected to happen in 2023. However, in the meantime, the company continues to generate consistent FCF that was $19.75 billion in 2021, down just a shade from the over $20 billion it generated in 2021.
And that growth is reflected in the company’s dividend which Johnson & Johnson just increased for the 61st consecutive year. This will keep JNJ in the exclusive group of stocks known as Dividend Kings.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $146.67
- Consensus Rating
- Hold
- Ratings Breakdown
- 5 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $174.07 (18.7% Upside)
